MRTX0902

· Mirati Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MRTX0902, covering 2026-02-19 to 2026-02-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway [Phase 1]